|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET
|
Wolfgang Fendler, MD
Phillip Koo interviews Wolfgang Fendler about advancements in PSMA PET imaging and its prognostic capabilities. Dr. Fendler highlights that the PROMISE criteria, developed for standardized PSMA PET reporting, now show significant prognostic value in predicting overall survival in prostate cancer across all stages.
|
|
|
|
|
|
|
|
|
|
|
| Patient Selection for PSMA Radioligand Therapy |
| Ephraim Parent, MD, Ph.D. |
| Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy. Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. |
|
|
|
|
|
|
|
|
|
|
|
| COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection |
|
Phillip Koo, MD
|
| Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. |
|
|
|
|
|
|
|
|
|
|
|
| Localized Prostate Carcinoma: Discordant Findings on mpMRI and PSMA PET Case of the Month |
| Devaki Shilpa Surasi, MD, CMQ |
| Devaki Shilpa Surasi presents a case of localized prostate carcinoma with conflicting results on multiparametric MRI and PSMA PET. The patient had a biopsy confirming prostate adenocarcinoma, and the MRI showed a diffuse lesion with extraprostatic spread and seminal vesicle involvement. |
|
|
|
|
|
|
|
|
|
|
|
| Response Assessment in RPTs for Prostate Cancer: Everyone’s A Winner
|
| Louise Emmett, MBChB, FRACP, MD
|
| Louise Emmett discusses response assessment in radiopharmaceutical therapies for prostate cancer, focusing on the importance of biomarkers for predicting treatment outcomes. This presentation highlights that high PSMA SUVmean patients had excellent response rates to 177Lu PSMA, while low SUVmean patients responded better to cabazitaxel.
|
|
|
|
|
|
Combined Forced Diuresis and Late Acquisition on [68GA]GA-PSMA-11 Pet/CT for Biochemical Recurrent Prostate Cancer: A Clinical Practice-Oriented Study - Beyond the Abstract
|
| Matteo Bauckneht, MD, Ph.D. |
| The study explores the impact of combining forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT imaging for detecting biochemical recurrence in prostate cancer patients. While the additional late-phase imaging only slightly increased overall diagnostic accuracy, it significantly improved accuracy for detecting nodal recurrences and local uptake when rated by less experienced readers. |
|
|
|
|
|
|
|
|
|
|
| Prognostic PSMA-PET PROMISE Nomograms for Patients with Prostate Cancer |
| Wolfgang Fendler, MD |
| Wolfgang Fendler presents the prognostic value of PSMA-PET PROMISE nomograms for prostate cancer patients. These nomograms, based on PSMA-PET metrics and the PROMISE criteria, aim to standardize prostate cancer molecular imaging reporting and provide precise staging. The study involved a retrospective analysis of 1,612 patients, split into development and validation cohorts. |
|
|
|
|
|
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2) - Beyond the Abstract
|
| Robert Seifert MD, Matthias Eiber MD, Ph.D., and Wolfgang Fendler MD |
| PROMISE V2.0 is an updated framework for the standardized reporting of PSMA-PET imaging in prostate cancer, enhancing the miTNM score and introducing a standardized template for both qualitative and quantitative findings. This update includes criteria for treatment response assessment, which is crucial for clinical trials and routine practice, thereby promoting PSMA-PET as a superior tool for diagnosing and monitoring prostate cancer. |
|
|
|
|
|
| The SPARC Initiative (Standardized PSMA PET Analysis and Reporting Consensus) |
| Anders Bjartell, MD, Ph.D. |
| Anders Bjartell introduces the SPARC (Standardized PSMA PET Analysis and Reporting Consensus) initiative, aimed at creating a unified framework for PSMA-PET/CT reporting. This initiative seeks to standardize communications between nuclear medicine physicians and clinicians, incorporating various existing classifications like PROMISE and PSMA-RADS under one umbrella. The project involves a multidisciplinary panel and a structured Delphi process to achieve consensus, enhancing clarity in PSMA-PET usage and reporting across clinical and research settings. |
|
|
|
|
|
| PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patients |
| Rashid Sayyid, MD, MSc |
| Rashid Sayyid presents findings on PSMA PET/CT-detected mesorectal nodal metastasis in biochemically recurrent prostate cancer patients. The study revealed that approximately 11% of patients exhibited mesorectal lymph node metastasis, which falls outside the typical lymphatic drainage zone of the prostate and is not typically targeted in standard treatments. |
|
|
|
|
|
